Blockchain Registration Transaction Record

NanoViricides Raises $3.8M for Broad-Spectrum Antiviral Drug Development

NanoViricides raises $3.8M in registered direct offering to fund NV-387 broad-spectrum antiviral drug development. Lead candidate targets RSV, COVID, Influenza, and MPOX.

This news matters because NanoViricides is advancing NV-387, a broad-spectrum antiviral that could address multiple viral threats including COVID-19, RSV, Influenza, and MPOX. The $3.8 million funding will support its progression into Phase II clinical trials, potentially leading to more effective treatments for respiratory infections. For investors, it signals continued financial backing and progress in the antiviral pipeline, which could have significant implications for public health and the biotech sector.